Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
CC transcript
Quarterly results
Appointed director
|
|
ACURA PHARMACEUTICALS, INC (ACUR)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/12/2023 |
8-K
| Quarterly results |
| 08/16/2023 |
8-K
| Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets Interacti... |
| 08/10/2023 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
| 07/28/2023 |
8-K
| Quarterly results |
| 07/28/2023 |
8-K
| Quarterly results |
| 07/13/2023 |
8-K
| Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financia... |
| 06/30/2023 |
8-K
| Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits Interactive Data |
| 06/30/2023 |
10-K
| Annual Report for the period ended December 31, 2021 |
| 06/30/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data|
Docs:
|
"ACURA PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS December 31, December 31, 2021 2020 Assets – current $ 372 $ 1,179 Property, plant and equipment, net 438 484 Other assets 50 73 Total assets $ 860 $ 1,736 Other liabilities - current $ 515 $ 680 Loan under CARES Act - current - 164 Accrued interest to related party – current - 678 Convertible debt to related party – current - 6,000 Loan under CARES Act – non current - 105 Promissory note to related party – non current 150 - Other liabilities – non current 17 - Stockholders' equity 178 Total liabilities and stockholders' equity $ 860 $ 1,736 ACURA PHARMACEUTICALS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS" |
|
| 05/26/2023 |
8-K
| Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financia... |
| 05/15/2023 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
| 03/20/2023 |
NT 10-K
| Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405: |
| 03/20/2023 |
8-K
| Quarterly results |
| 02/22/2023 |
8-K
| Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financia... |
| 02/13/2023 |
8-K
| Quarterly results |
| 02/02/2023 |
8-K
| Other Events Interactive Data |
| 01/20/2023 |
8-K
| Quarterly results |
| 01/05/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/05/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/05/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/05/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/05/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/05/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/05/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/05/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/27/2022 |
8-K
| Quarterly results |
| 11/14/2022 |
8-K
| Quarterly results |
| 11/04/2022 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
| 10/17/2022 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 09/26/2022 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 08/26/2022 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 08/05/2022 |
4
| Brzeczko Albert W (VP, Pharma Sciences - APT) has filed a Form 4 on ACURA PHARMACEUTICALS, INC|
Txns:
| Exercised 9,333 options to buy
@ $0
Exercised 34,000 options to buy
@ $0 |
|
| 08/05/2022 |
4
| Jones Robert B (President & CEO) has filed a Form 4 on ACURA PHARMACEUTICALS, INC|
Txns:
| Exercised 13,666 options to buy
@ $0
Exercised 50,000 options to buy
@ $0 |
|
| 08/05/2022 |
4
| Seiser Robert A (VP, Controller & Treasurer) has filed a Form 4 on ACURA PHARMACEUTICALS, INC|
Txns:
| Exercised 4,666 options to buy
@ $0
Exercised 20,000 options to buy
@ $0 |
|
|
|
|